Dataset Information

Irinotecan and retetrasse combined with radiotherapy with or without bevacizumab in patients with recurrent colorectal cancer: a multicenter, prospective, randomized controlled clinical trial

ABSTRACT: Interventions: control group:Irinotecan was given intravenously at week 1, week 3 and week 5, 180 mg / m2; Retetrasse was given intravenous drip of 2 mg / m2 for 1 day at 1, 3 and 5 weeks; Concurrent radiotherapy: IMRT external radiotherapy.;Experimental group:Irinotecan was given intravenously at week 1, week 3 and week 5, 180 mg / m2; Retetrasse was given intravenous drip of 2 mg / m2 for 1 day at 1, 3 and 5 weeks; Bevacizumab was given intravenously for 1 day at week 1, 3 and 5; Concurrent radiotherapy: IMRT external radiotherapy. Primary outcome(s): Objective response rate Study Design: Parallel

DISEASE(S): Colorectal Cancer

PROVIDER: 2699734 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Similar Datasets

Project description:Intervention 1: ?1st Arm: Short course radiotherapy with 25 Gy in 5 fractions with concurrent chemotherapy regimen including Capecitabine 625mg/m2/bid for 5 days and Oxaliplatin 50mg/m2/day for 1 day then one cycle chemotherapy with XELOX regimen (Capecitabine 1000mg/m2/bid for 14 days and Oxaliplatin 130mg/m2/day for 1 day) 3 - 4 weeks after completion of radiotherapy then surgery at least 8 weeks after the radiotherapy last session. Intervention 2: 2nd Arm (Control): Long course radiotherapy with 50 Gy in 25 fractions with concurrent Capecitabine 825mg/m2/bid for 5 days each week then one cycle chemotherapy with XELOX regimen (Capecitabine 1000mg/m2/bid for 14 days and Oxaliplatin 130mg/m2/day for 1 day) 3 - 4 weeks after completion of radiotherapy then surgery at least 8 weeks after the radiotherapy last session.;Treatment - Drugs;Treatment - Drugs;?1st Arm: Short course radiotherapy with 25 Gy in 5 fractions with concurrent chemotherapy regimen including Capecitabine 625mg/m2/bid for 5 days and Oxaliplatin 50mg/m2/day for 1 day then one cycle chemotherapy with XELOX regimen (Capecitabine 1000mg/m2/bid for 14 days and Oxaliplatin 130mg/m2/day for 1 day) 3 - 4 weeks after completion of radiotherapy then surgery at least 8 weeks after the radiotherapy last session.;2nd Arm (Control): Long course radiotherapy with 50 Gy in 25 fractions with concurrent Capecitabine 825mg/m2/bid for 5 days each week then one cycle chemotherapy with XELOX regimen (Capecitabine 1000mg/m2/bid for 14 days and Oxaliplatin 130mg/m2/day for 1 day) 3 - 4 weeks after completion of radiotherapy then surgery at least 8 weeks after the radiotherapy last session. Primary outcome(s): Complications. Timepoint: At the Initiation of Radiotherapy up to one month after surgery. Method of measurement: Common terminology criteria for cancer related therapy adverse events. Study Design: Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.

Dataset Information

Irinotecan and retetrasse combined with radiotherapy with or without bevacizumab in patients with recurrent colorectal cancer: a multicenter, prospective, randomized controlled clinical trial

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure